ArticleFrontiers in oncology2024
Total retroperitoneal lipectomy improves prognosis in patients with primary retroperitoneal liposarcoma: a comparative study.
Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Long-term survival with eribulin in an elderly patient with inoperable retroperitoneal well-differentiated liposarcoma: a case report and literature review.Frontiers in oncology · 2026Article
- ARNT2-driven transcriptional activation of STRA6 reprograms fatty acid metabolism to promote retroperitoneal liposarcoma progression.Journal of cancer research and clinical oncology · 2025Article
- Challenges and hope: latest research trends in the clinical treatment and prognosis of liposarcoma.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Retroperitoneal liposarcoma (RPLS) is the most common soft tissue sarcoma originating in the retroperitoneal space. Although surgery is the standard treatment, recurrence remains frequent. In this study, we aimed to explore the safety and efficacy of total (ipsilateral) retroperitoneal lipectomy (TRL) compared to traditional complete resection (CR) for primary RPLS. Methods: We retrospectively analyzed patients with primary RPLS treated at our center between January 2014 and December 2020. Univariate and multivariable Cox regression analyses assessed the impact of demographic, operative, and clinicopathological variables on recurrence-free survival (RFS) and overall survival (OS). Kaplan-Meier plots illustrated RFS and OS, and the log-rank test compared time-to-event distributions. Results: A total of 81 patients were included in the final analysis: 37 in the CR group and 44 in the TRL group. Demographic and clinicopathologic parameters were comparable between the two groups. Post-operative morbidity occurred in 30.9% of cases, with 15 (40.5%) in the CR group and 10 (22.7%) in the TRL group (P=0.086). There were 9 cases of severe complications at grade 3 or higher, with 5 cases in the CR group and 4 cases in the TRL group. There was no significant difference between the two groups (P=0.314). The TRL group demonstrated improved RFS and OS, particularly among dedifferentiated liposarcoma (DDLS) patients. Conclusions: Total retroperitoneal lipectomy (TRL) appears to be a safe procedure that enhances survival outcomes in patients with primary RPLS. Further studies are needed to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.